1.LUNAI PHARMACEUTICAL: In the first quarter of 2021, the company's net profit of 47.96 million, an increase of 693.98% over the previous year. The current market capitalization of 6.567 billion. June 9 news, today LUXA Pharmaceuticals opened at 7.43 yuan, as of 15:00 closing, the stock fell 0.53% at 7.46 yuan.
Today's (June 9) funds net -16.329 million yuan, oversized single net -5.0211 million yuan, turnover rate of 0.63%, turnover amount of 41.4673 million yuan.
2. North China Pharmaceutical: in the first quarter of 2021, the company's net profit -57.2 million, compared with the previous year's growth rate of -185.74%.
June 9 closing news, North China Pharmaceutical 600812 closed up 7.14% at 11.85. market value of 20.211 billion yuan.
June 8 the stock main net -43.2996 million yuan, super-large net -22.9165 million yuan, large net -20.3832 million yuan, in the single net 12.6517 million yuan, retail net 12.06 yuan.
The stock of the concept of epidemic prevention:
1, the spotlight science and technology: 2020 net profit of 489 million, an increase of 1128.82%.
February 21, 2020 the company said on the interactive platform, CDC around the world is the company's subsidiary Jitian Instruments customers, the main products are atomic fluorescence photometer and flow injection analyzer, there are products put into the Hubei, Yunnan region of the anti-epidemic epidemic prevention.
2, panglong pharmaceutical: 2020 annual report shows, panglong pharmaceutical realized net profit of 79.12 million yuan, an increase of 10.22%.
The company's first batch of production of 75% mono ethanol disinfectant products have now been put on the front line of the anti-epidemic, the company will speed up the production of 75% mono ethanol disinfectant, and make every effort to meet the market demand for materials for the prevention and control of epidemics.
3, the beauty of health: 2020 annual report shows that the beauty of health to achieve net profit of 554 million yuan.
The company for the resumption of work anti-epidemic screening work, has launched two programs, including "new coronavirus nucleic acid testing program" is to viral nucleic acid testing as the main project, "in-depth lung examination program" is to low-dose helical CT imaging as the main project. The "In-depth Lung Examination Program" is a low-dose spiral CT imaging program.
4, Myriad Medical: 2020 net profit of 6.658 billion, an increase of 42.24%.
20 years in March, the company has received overseas including Asia-Pacific, Europe, the Middle East and other regions in response to the epidemic and the procurement needs, recently due to the rapid warming of the epidemic in Italy, the Italian government emergency to the Myriad procurement of nearly 10,000 units of anti-epidemic equipment, including monitors and respiratory machines and other products.
5, Zongsheng Pharmaceutical: the company's net profit in 2020 -427 million yuan, up -234.27%.
20 years in February, the company's production of chloroquine phosphate tablets will be handed over to the Guangdong Province, the new coronavirus infected pneumonia epidemic prevention and control command materials to protect a group of storage, the company will be combined with all the strength of chloroquine phosphate tablets of mass production, to help win the "anti-epidemic" resistance war.
6, Fosun Pharmaceuticals: 2020 net profit of 3.663 billion, an increase of 10.27%.